• Nelfinavir Mesylate: Applied HIV-1 Protease Inhibition & Bey

  2026-04-28

  Nelfinavir Mesylate stands out as an HIV-1 protease inhibitor with proven efficacy in both classic antiretroviral workflows and emerging ferroptosis modulation. This guide delivers actionable protocols, troubleshooting wisdom, and fresh insights from recent research—empowering scientists to harness its full translational potential.

• Transcriptional Elongation Inhibition: DRB’s Impact on Cell

  2026-04-28

  This thought-leadership article explores 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) as a multifaceted tool for translational researchers. Bridging mechanistic insights from cyclin-dependent kinase inhibition and transcriptional elongation, we examine how DRB enables precise control over gene expression, cell fate transitions, and antiviral responses. By contextualizing DRB’s action within current advances—such as m6A-driven phase separation and the IkB-NF-kB-CCND1 axis—this piece delivers actionable strategies for experimental design. It also highlights protocol nuances, cross-domain opportunities, and the future landscape for stem cell and antiviral research.

• O-GlcNAcylation Links Wnt Signaling to Bone Anabolism via Gl

  2026-04-27

  This study reveals that Wnt3a-driven bone formation depends on O-GlcNAcylation, a post-translational modification that rewires glycolytic metabolism in osteoblasts. By mapping the mechanism to the Ca2+-PKA-GFAT1 axis and stabilization of PDK1, the research provides new insight into how Wnt signaling modulates osteogenesis and tissue regeneration.

• Disrupting the c-Myc Axis: 10074-G5 in Translational Oncolog

  2026-04-27

  This thought-leadership article examines how 10074-G5, a small-molecule c-Myc inhibitor from APExBIO, empowers translational researchers to functionally dissect and therapeutically target the c-Myc/Max axis in aggressive cancers. We integrate recent mechanistic insights—such as the MYC/TERT/NFκB signaling loop in esophageal adenocarcinoma—and provide strategic, evidence-labeled protocol guidance. By bridging molecular oncology and workflow optimization, the article positions 10074-G5 as a next-generation tool for advancing apoptosis assays, cell cycle arrest studies, and tumor regression research, while articulating translational implications beyond the standard product narrative.

• D-Luciferin Sodium Salt: Illuminating CAR Macrophage Therapi

  2026-04-26

  Explore how D-Luciferin sodium salt advances next-generation bioluminescent imaging for translational oncology, with a special focus on its role in validating CAR macrophage therapies for peritoneal metastasis. This article bridges mechanistic insight, experimental best practices, and strategic guidance for researchers seeking rigor and innovation.

• Vernakalant Hydrochloride: Precision Workflows for AF Conver

  2026-04-25

  Vernakalant Hydrochloride (RSD1235) empowers translational and preclinical researchers with unmatched atrial selectivity, rapid AF conversion, and robust experimental flexibility. This guide delivers actionable protocol enhancements, troubleshooting insights, and evidence-labeled parameters to accelerate high-fidelity atrial fibrillation research.

• Targeting p-tau Ser356: NUAK1 Inhibition in Alzheimer’s Mode

  2026-04-24

  Taylor et al. (2023) identify tau phosphorylation at Ser356 as a marker closely linked to Alzheimer’s disease progression and demonstrate that pharmacological NUAK1 inhibition with WZ4003 can specifically decrease this pathogenic tau form in human brain tissue. These findings offer new mechanistic insights for targeted tauopathy interventions and inform translational strategies for disease modeling.

• Prosapogenin A Triggers GSDME-Linked Pyroptosis in ATC via L

  2026-04-24

  This study uncovers how Prosapogenin A induces GSDME-dependent pyroptosis in anaplastic thyroid cancer (ATC) cells through V-ATPase-mediated lysosomal over-acidification and membrane permeabilization. The findings reveal a new therapeutic avenue targeting lysosomal fragility in aggressive cancers and highlight mechanistic contrasts with caspase-centric apoptosis strategies.

• HyperTrap Heparin HP Column: Beyond Purity—Precision in Canc

  2026-04-23

  Explore how the HyperTrap Heparin HP Column empowers reproducible, high-resolution purification for cancer stem cell research. Learn how its advanced chromatography medium enhances experimental rigor and unlocks new avenues for dissecting signaling mechanisms.

• Gold(I) Complex GC002 Induces Necroptosis via TrxR Inhibitio

  2026-04-23

  This study identifies the gold(I) phosphine complex GC002 as a potent inducer of necroptosis in hepatocellular carcinoma (HCC) cells through direct inhibition of thioredoxin reductase (TrxR) and ROS accumulation. The results highlight GC002's superior antitumor activity compared to clinically used agents and its potential as a targeted therapy for HCC.

• CRISPR/Cas9-Mediated Knockout of ABCB1 Reverses Tumor Drug R

  2026-04-22

  This study demonstrates that CRISPR/Cas9 genome editing can specifically disrupt the ABCB1 gene in multidrug-resistant (MDR) cancer cells, significantly restoring their sensitivity to chemotherapeutic agents. The findings provide a technical framework for targeting efflux pump-mediated drug resistance and offer new avenues for functional genomics in cancer research.

• Paclitaxel (Taxol): Precision Dosing and Assay Optimization

  2026-04-22

  Explore Paclitaxel (Taxol) as a microtubule stabilizer with a unique focus on quantitative assay optimization, advanced dosing parameters, and benchmark comparisons in cancer research. This article provides actionable insights for designing robust experiments in oncology.

• SGC-CBP30: Disrupting Super-Enhancer Hijacking in Lung Cance

  2026-04-21

  This article unpacks the emerging role of CREBBP/EP300 bromodomain inhibitors—specifically SGC-CBP30—in targeting super-enhancer hijacking and transcriptional coactivator addiction in early-stage lung adenocarcinoma. Integrating mechanistic evidence, translational workflow guidance, and a competitive landscape analysis, it spotlights SGC-CBP30 as a precision tool for epigenetics and cancer biology research. The discussion advances beyond standard product pages by providing actionable protocol parameters, cross-study insights, and a visionary outlook for translational researchers.

• Novel 14-3-3 Interactors ATG9A and PTOV1 in Cancer Regulatio

  2026-04-21

  This study identifies ATG9A and PTOV1 as novel 14-3-3 binding proteins, unraveling their distinct mechanistic roles in autophagy and oncogenic stability, respectively. Through proteomic and biochemical interrogation, the work illuminates new regulatory axes in cancer biology and suggests tractable pathways for therapeutic exploration.

• Selective Autophagy Regulates IRF3 Stability and Type I IFN

  2026-04-20

  Wu et al. reveal that selective autophagy, mediated by CALCOCO2/NDP52 and regulated by PSMD14, targets the transcription factor IRF3 for degradation in a virus load-dependent manner. This mechanism ensures precise control of type I interferon responses and highlights new layers of innate immune regulation.

421 records 18/29 page Previous Next First page 上5页 1617181920 下5页 Last page